Corvus Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
De CEO Corvus Pharmaceuticals is Rick Miller, benoemd in Feb2014, heeft een ambtstermijn van 10.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.32M, bestaande uit 8.3% salaris en 91.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.82% van de aandelen van het bedrijf, ter waarde $ 16.69M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.9 jaar en 9.5 jaar.
Belangrijke informatie
Rick Miller
Algemeen directeur
US$1.3m
Totale compensatie
| Percentage CEO-salaris | 8.3% |
| Dienstverband CEO | 10.8yrs |
| Eigendom CEO | 2.8% |
| Management gemiddelde ambtstermijn | 4.9yrs |
| Gemiddelde ambtstermijn bestuur | 9.5yrs |
Recente managementupdates
Recent updates
Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy
Sep 02Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?
Mar 06
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Oct 23Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?
May 16Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Dec 05Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China
Sep 26We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate
Aug 14Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth
Apr 05We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely
Dec 15Checking In On Corvus Pharmaceuticals
Dec 10Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming
Sep 22We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth
Aug 26Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target
May 27Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
May 08The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares
Feb 19Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation
Feb 07Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
Dec 16Corvus Pharmaceuticals EPS misses by $0.06
Oct 29Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$23m |
| Mar 31 2024 | n/a | n/a | -US$25m |
| Dec 31 2023 | US$1m | US$110k | -US$27m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$39m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$524k | US$300k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$37m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | US$905k | US$300k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$7m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$1m | US$300k | -US$6m |
| Sep 30 2020 | n/a | n/a | -US$44m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$48m |
| Dec 31 2019 | US$1m | US$300k | -US$47m |
| Sep 30 2019 | n/a | n/a | -US$46m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$1m | US$300k | -US$47m |
| Sep 30 2018 | n/a | n/a | -US$48m |
| Jun 30 2018 | n/a | n/a | -US$51m |
| Mar 31 2018 | n/a | n/a | -US$54m |
| Dec 31 2017 | US$1m | US$302k | -US$56m |
Compensatie versus markt: De totale vergoeding ($USD 1.32M ) Rick } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.34M ).
Compensatie versus inkomsten: De vergoeding van Rick is gestegen terwijl het bedrijf verliesgevend is.
CEO
Rick Miller (73 yo)
10.8yrs
Tenure
US$1,321,351
Compensatie
Dr. Richard A. Miller, also known as Rick, M.D., serves as Director of BrainScope Company Inc. since September 2023. He is a Co-Founder of Corvus Pharmaceuticals, Inc. and has been its Chief Executive Offi...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 10.8yrs | US$1.32m | 2.82% $ 16.7m | |
| Co-Founder & Independent Director | no data | US$95.35k | geen gegevens | |
| Chief Financial Officer | 10yrs | US$660.76k | 0.45% $ 2.7m | |
| Senior Vice President of Pharmaceutical Development | 4.9yrs | US$616.26k | 0.25% $ 1.5m | |
| Senior Vice President of Research | 2.3yrs | geen gegevens | geen gegevens | |
| Chief Business Officer | less than a year | geen gegevens | geen gegevens |
4.9yrs
Gemiddelde duur
67yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CRVS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 10.8yrs | US$1.32m | 2.82% $ 16.7m | |
| Co-Founder & Independent Director | 10yrs | US$95.35k | geen gegevens | |
| Independent Director | 10yrs | US$101.35k | geen gegevens | |
| Independent Director | 5.8yrs | US$97.35k | 0.016% $ 94.5k | |
| Independent Director | 7.8yrs | US$93.35k | geen gegevens | |
| Independent Director | 8.9yrs | US$109.35k | geen gegevens |
9.5yrs
Gemiddelde duur
66.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CRVS wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.5 jaar).